オプションチェーンは、Cybinの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cybinの市場センチメントを評価します。.

Cybin (AMEX:CYBN) 株価情報, オプションチェーン

Cybin

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.

Cybin Inc

Cyber Security 1 AB ADR

Rosenblatt analyst Mike Genovese maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Buy and maintains $285 price target.

News

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Fabrinet, Maintains $285 Price Target

Bloomberg Reported Liberty Global Has Approached Vodafone For A Potential Acquisition Of Its Stake In Dutch JV VodafoneZiggo

Rosenblatt analyst Mike Genovese maintains Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) with a Buy and maintains $36 price target.

AAOI

Rosenblatt Maintains Buy on Applied Optoelectronics, Maintains $36 Price Target

Needham analyst Scott Berg reiterates DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Hold to Hold.

Reiteration

DOCU

Needham Reiterates Hold on DocuSignto Hold

Rosenblatt analyst Blair Abernethy maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Buy and raises the price target from $77 to $82.

RBRK

Rosenblatt Maintains Buy on Rubrik, Raises Price Target to $82

Benchmark analyst Cody Acree maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and lowers the price target from $82 to $68.

SMTC

Benchmark Maintains Buy on Semtech, Lowers Price Target to $68

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $125 price target.

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target

Food company Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading higher in premarket</a> on Friday.
The company has introduced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44323543/pilgrims-announces-1-5-billion-special-dividend-and-long-term-capital-allocation-strategy" rel="noreferrer noopener">capital allocation strategy </a>designed to strengthen its financial position, broaden its diverse portfolio, and generate long-term value for its shareholders.
As a component of this initiative, the board has approved a special cash dividend of $6.30 per share. With the current share count, the total special dividend payout is approximately $1.5 billion.
This payment will be made on April 17, 2025, to shareholders on record as of April 3, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44305204/metas-community-notes-to-replace-third-party-fact-checkers" rel="noreferrer noopener">Meta&#8217;s Community Notes To Replace Third-Party Fact Checkers</a>
&#8220;Pilgrim&#8217;s is confident in the future of our business and we believe our capital allocation strategy positions the company for continued, disciplined growth and enhanced earnings potential across our diversified portfolio,&#8221; said CEO Fabio Sandri.
&#8220;The Board&#8217;s decision to pay a special dividend reflects our strong balance sheet and our commitment to create long-term stockholder value.&#8221;
In addition to the dividend, Pilgrim&#8217;s Pride has outlined steps to further strengthen its business operations.
The company is focusing on key areas such as expanding its prepared foods segment, increasing small bird production for key customer demands, and transforming a major bird facility into a case-ready plant to support retail growth.
Furthermore, Pilgrim&#8217;s plans to boost protein conversion capacity to enhance its product offerings and minimize risk.
Over the past five years, Pilgrim&#8217;s Pride has committed huge capital to various initiatives, including more than $950 million in acquisitions, $1.8 billion in share buybacks and dividends, and $2.2 billion in capital expenditures.
Price Action: PPC shares traded higher by 5.39% at $52.98 in premarket on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44301525/canadian-imperial-bank-picks-harry-culham-as-next-ceo" target="_blank" rel="noreferrer noopener">Canadian Imperial Bank Picks Harry Culham As Next CEO</a></li>
</ul>
Image via Shutterstock.

Equities

Dividends

Movers

General

Why Is Poultry Producer Pilgrim's Pride Stock Surging Today?

Piper Sandler analyst Korinne Wolfmeyer maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Neutral and lowers the price target from $425 to $364.

ULTA

Piper Sandler Maintains Neutral on Ulta Beauty, Lowers Price Target to $364

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 10.33%</li>
<li>RBC Capital analyst Michael Carroll maintained an Underperform rating and cut the price target from $12 to $11 on March 10, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and lowered the price target from $14 to $13 on Dec. 6, 2024. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Feb. 25, Easterly Government Props posted fourth-quarter FFO of 29 cents, in-line with estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest DEA <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png" alt="" class="wp-image-824364" style="width:475px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033554/image-119-768x710.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>)</h3>
<ul>
<li>Dividend Yield: 9.17%</li>
<li>UBS analyst Robin Farley maintained a Neutral rating and cut the price target from $15 to $13 on Feb. 3, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Wolfe Research analyst Keegan Carl downgraded the stock from Outperform to Peer Perform on Sept. 26, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Feb. 19, Park Hotels &amp; Resorts posted better-than-expected quarterly revenue.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">latest PK news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="900" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png" alt="" class="wp-image-824366" style="width:492px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033629/image-120-768x714.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">Healthcare Realty Trust Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>)</h3>
<ul>
<li>Dividend Yield: 7.60%</li>
<li>Wedbush analyst Richard Anderson downgraded the stock from Neutral to Underperform and cut the price target from $18 to $16 on Jan. 2, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Wells Fargo analyst James Feldman assumed an Underweight rating and raised the price target from $16 to $17 on Oct. 1, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Feb. 19, Healthcare Realty Trust reported quarterly earnings of 40 cents per share.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">HR news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png" alt="" class="wp-image-824369" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14033711/image-121-768x712.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

Needham analyst Quinn Bolton reiterates D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy and maintains $8.5 price target.

QBTS

Needham Reiterates Buy on D-Wave Quantum, Maintains $8.5 Price Target

Needham analyst Quinn Bolton reiterates Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and maintains $54 price target.

Needham Reiterates Buy on Semtech, Maintains $54 Price Target

Piper Sandler analyst Peter Keith maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Neutral and raises the price target from $79 to $81.

Piper Sandler Maintains Neutral on Dollar Gen, Raises Price Target to $81

Piper Sandler analyst Quinton Gabrielli maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Overweight and lowers the price target from $268 to $200.

MANH

Piper Sandler Maintains Overweight on Manhattan Associates, Lowers Price Target to $200

Needham analyst Chris Pierce reiterates Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) from Hold to Hold.

BLNK

Needham Reiterates Hold on Blink Chargingto Hold

Needham analyst Gil Blum reiterates Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) with a Buy and maintains $8 price target.

GBIO

Needham Reiterates Buy on Generation Bio, Maintains $8 Price Target

AAOI: 92% &#x7C; <a href="https://www.benzinga.com//node/44317133">Applied Optoelectronics shares are trading higher after the company announced a warrant issuance agreement transaction with Amazon for 7,945,399 shares.</a>
&nbsp;
SMTC: 13% &#x7C; <a href="https://www.benzinga.com//node/44316016">Semtech shares are trading higher after the company reported better-than-expected Q4 financial results.</a>
&nbsp;
RBRK: 21% &#x7C; <a href="https://www.benzinga.com//node/44315877">Rubrik shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 guidance above estimates.</a>

Market-Moving News for March 14th

Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) reported stronger-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/ulta/earnings">financial results on Thursday</a>.
Ulta Beauty reported fourth-quarter revenue of $3.49 billion, beating the consensus estimate of $3.46 billion. The specialty beauty retailer reported fourth-quarter earnings of $8.46 per share, beating analyst estimates of $7.14 per share, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
"I am incredibly optimistic about the future of Ulta Beauty, as I believe we have the right elements to drive our success — a strong business model, an ambitious long-term plan, and passionate associates who bring our brand to life for our guests every day," said Kecia Steelman, president and CEO of Ulta Beauty.
Ulta Beauty expects fiscal year 2025 revenue of $11.5 billion to $11.6 billion versus estimates of $11.67 billion, according to Benzinga Pro. The company anticipates full-year earnings of $22.50 to $22.90 per share versus estimates of $23.50 per share.
Ulta Beauty shares fell 4.5% to close at $314.47 on Thursday.
These analysts made changes to their price targets on Ulta Beauty following earnings announcement.
<ul>
<li>Morgan Stanley analyst Simeon Gutman maintained Ulta Beauty with an Overweight rating and lowered the price target from $500 to $460.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained the stock with an Outperform rating and cut the price target from $500 to $460.</li>
</ul>
Considering buying ULTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-1024x611.png" alt="" class="wp-image-824610" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14070950/image-122.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44323490/ulta-beauty-docusign-and-3-stocks-to-watch-heading-into-friday">Ulta Beauty, DocuSign And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Earnings

Ulta Beauty Analysts Slash Their Forecasts After Q4 Results

Telsey Advisory Group analyst Dana Telsey maintains Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) with a Market Perform and maintains $5 price target.

CURV

Telsey Advisory Group Maintains Market Perform on Torrid Holdings, Maintains $5 Price Target

PLTR

Palantir Technologies Partners With R1 To Launch R37 AI Lab, Revolutionizing Healthcare Financial Performance With Advanced Automation Solutions

Press Releases

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Comments

Cybin

Cybin (CYBN) オプション

Cybin (AMEX:CYBN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル